RNA 8-K furnishes press release for quarter ended September 2025

Rhea-AI Filing Summary

Avidity Biosciences (RNA) furnished quarterly results information via Form 8-K. The company reported that it issued a press release announcing financial results for the quarter ended September 30, 2025, and attached the release as Exhibit 99.1. The Item 2.02 information, including Exhibit 99.1, is provided under General Instruction B.2 and is not deemed filed for liability purposes under the Exchange Act.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001599901FALSE00015999012025-11-102025-11-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________________________________

FORM 8-K

_________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 10, 2025

_________________________________________

AVIDITY BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

_________________________________________

Delaware			001-39321			46-1336960
(State or other jurisdiction of incorporation or organization)			(Commission File Number)			(I.R.S. Employer Identification No.)

3020 Callan Road

San Diego, California 92121

(Address of principal executive offices) (Zip Code)

(858) 401-7900

(Registrant’s telephone number, include area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

_________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

RNA

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02. Results of Operations and Financial Condition.

On November 10, 2025, Avidity Biosciences, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number						Description
99.1						Press Release issued on November 10, 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			AVIDITY BIOSCIENCES, INC.
Date: November 10, 2025			By:			/s/ Michael F. MacLean
						Michael F. MacLean Chief Financial Officer

FAQ

What did Avidity Biosciences (RNA) announce in this 8-K?

The company furnished a press release announcing financial results for the quarter ended September 30, 2025, attached as Exhibit 99.1.

Which 8-K item applies to Avidity Biosciences (RNA)?

The disclosure is under Item 2.02 (Results of Operations and Financial Condition).

Is the information considered filed or furnished?

It is provided under General Instruction B.2 and is not deemed filed for purposes of Section 18 of the Exchange Act.

What period do the results cover for RNA?

The filing references the quarter ended September 30, 2025.

Which exhibit contains the press release?

The press release is attached as Exhibit 99.1.

Who signed the report for Avidity Biosciences?

It was signed by Michael F. MacLean, Chief Financial Officer.

Where is Avidity Biosciences listed and what is its ticker?

Common stock trades on The Nasdaq Global Market under the symbol RNA.